Welcome to our dedicated page for Eledon Pharmaceuticals news (Ticker: ELDN), a resource for investors and traders seeking the latest updates and insights on Eledon Pharmaceuticals stock.
Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) is a clinical stage biotechnology company developing immune-modulating therapies centered on the CD40 Ligand (CD40L) pathway. The company’s news flow largely reflects progress with its lead investigational product, tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand that Eledon describes as having broad therapeutic potential.
News updates for ELDN commonly cover clinical trial milestones in kidney allograft transplantation, islet cell transplantation, xenotransplantation and amyotrophic lateral sclerosis (ALS). For example, Eledon has issued press releases on Phase 2 BESTOW trial results in de novo kidney transplant recipients, highlighting kidney function outcomes, safety and tolerability compared with tacrolimus-based regimens. Additional announcements have detailed updated data from a Phase 1b open-label kidney transplant study and long-term extension work.
Another recurring theme in Eledon’s news is the use of tegoprubart in islet transplantation for individuals with type 1 diabetes. The company has reported preliminary results from an investigator-initiated trial at the University of Chicago Medicine’s Transplant Institute, describing insulin independence and improved glycemic control in the first treated subjects. Eledon also issues updates on tegoprubart’s role in xenotransplantation, including its use as a key component of immunosuppression regimens in pig-to-human kidney transplant procedures at Massachusetts General Hospital.
Investors following ELDN news can also expect announcements related to scientific conference presentations, participation in healthcare conferences, financing transactions such as underwritten public offerings of common stock and pre-funded warrants, and selected financial results. This news page aggregates such disclosures so readers can review Eledon’s reported clinical data, corporate developments and regulatory-related communications over time.
Eledon Pharmaceuticals (NASDAQ: ELDN) has reached a significant milestone in its Phase 2 BESTOW trial, enrolling 80 participants, which represents two-thirds of the projected recruitment for evaluating tegoprubart in preventing kidney transplant rejection. The multicenter study, comparing tegoprubart to tacrolimus, aims to enroll approximately 120 participants across the United States, Europe, and Latin America. The trial's primary objective is to assess graft function at 12 months post-transplant using estimated glomerular filtration rate (eGFR). Eledon's CEO, David-Alexandre C. Gros, M.D., expressed gratitude for the high level of interest and emphasized the urgency for innovative solutions in transplant rejection prevention. The company remains on track to complete enrollment by the end of the year.
Eledon Pharmaceuticals (Nasdaq: ELDN) will be participating in the Leerink Partners Therapeutics Forum focused on Inflammation & Immunology (I&I) and Metabolism. The event is scheduled for July 9, 2024, in Boston, MA. During the forum, Eledon's management team will engage in one-on-one meetings with investors and industry professionals. This participation highlights Eledon's active role in the field of therapeutics and its ongoing efforts to engage with key stakeholders.
Eledon Pharmaceuticals presented updated data from its ongoing Phase 1b trial of tegoprubart for preventing organ rejection in kidney transplant patients at the American Transplant Congress.
The study involved 13 participants and demonstrated a consistent mean eGFR of 70.5 mL/min/1.73m² at all reported time points post-transplant. Notably, two participants had mean eGFRs above 90 mL/min/1.73m² at 12 months post-transplant.
Tegoprubart was generally well tolerated, with no cases of hyperglycemia, new onset diabetes, or tremor, commonly seen with current calcineurin inhibitor-based treatments. Three participants discontinued the study due to adverse effects, including hair loss, viral infection, and rejection.
Eledon is also running a Phase 2 BESTOW trial with expected enrollment completion by year-end 2024.
Eledon Pharmaceuticals reported its first quarter 2024 financial results, highlighting an oversubscribed $50 million private placement. The company dosed the first participant in a clinical trial at the University of Chicago assessing tegoprubart for islet cell transplant rejection in type 1 diabetes patients. They also shared data from a Phase 1b trial for kidney transplantation and the use of tegoprubart in xenotransplantation. Eledon anticipates significant milestones in 2024 and ended the quarter with $42.9 million in cash.
Eledon Pharmaceuticals, Inc. will present updated data from an ongoing Phase 1b trial of tegoprubart at the American Transplant Congress. The trial focuses on preventing rejection in kidney transplant patients. The company will also sponsor a symposium on solid organ transplantation. Details can be found on the company's website.
Eledon Pharmaceuticals, Inc. announced the dosing of the first participant in a clinical trial at the University of Chicago Medicine using tegoprubart to prevent islet cell transplant rejection in type 1 diabetes patients. They also reported positive results from a Phase 1b trial for kidney transplant rejection prevention. Tegoprubart demonstrated safety and effectiveness in protecting organ function in kidney transplant patients with no cases of graft loss or death. The company plans to present the data at the American Transplant Congress. Eledon is conducting multiple trials to evaluate tegoprubart for preventing organ rejection in kidney transplant recipients, showcasing its potential as a promising treatment option.
Eledon Pharmaceuticals announced an oversubscribed $50 million private placement deal with institutional investors, including BVF Partners LP. The financing involves the sale of common stock and pre-funded warrants at specific prices. The net proceeds will be used for pre-commercial activities and general corporate purposes, including the clinical development of its lead product tegoprubart.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Eledon Pharmaceuticals (ELDN)?
What is the market cap of Eledon Pharmaceuticals (ELDN)?
